References

Ablashi DV, Eastman HB, Owen CB, Roman MM, Friedman J, Zabriskie JB, Peterson DL, Pearson GR, Whitman JE. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol. 2000 May;16(3):179-91.

Ablashi DV, Levine PH, DeVinci C et al. Use of anti HHV-6 transfer factor for the treatment of two patients with chronic fatigue syndrome (CFS). Two case reports. Biotherapy 1996;9:81-86.

Basten A, McLeod JG, Pollard JD, Walsh JC, Stewart GJ, Garrick R, Frith JA, Van Der Brink CM.Transfer factor in treatment of multiple sclerosis. Lancet. 1980 Nov 1;2(8201):931-4.

Bennett MP, Zeller JM, Rosenberg L, McCann J. The effect of mirthful laughter on stress and natural killer cell activity.
Altern Ther Health Med. 2003 Mar-Apr;9(2):38-45.

Cantorna MT. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease.
Prog Biophys Mol Biol. 2006 Sep;92(1):60-4.

Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuro-Psychopharm Biologic Psychiatry 2006;30:899-905.

Cruess DG, Antoni MH, Gonzalez J, Fletcher MA, Klimas N, Duran R, Ironson G, Schneiderman N. Sleep disturbance mediates the association between psychological distress and immune status among HIV-positive men and women on combination antiretroviral therapy. J Psychosom Res. 2003 Mar;54(3):185-9.

Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2006 Nov 4 ahead of print

Diamond M, Kelly JP, Connor TJ. Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. European Neuropsychopharmacology 2006;16:481-490.

Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trialArch Gen Psychiatry. 1998 Oct;55(10):883-9.

Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, Chavez R, Correa B, Monges A, Cabezas R, Calva C, Estrada-Garcia I. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int J Immunopharmacol. 1998 Oct;20(10):521-35.

Estrada-Parra S, Chavez-Sanchez R, Ondarza-Aguilera R, Correa-Meza B, Serrano-Miranda E, Monges-Nicolau A, Calva-Pellicer C. Immunotherapy with transfer factor of recurrent herpes simplex type I. Arch Med Res. 1995;26 Spec No:S87-92.

Faber WR, Leiker DL, Nengerman IM, Schellekens PT. A placebo controlled clinical trial of transfer factor in lepromatous leprosy. Clin Exp Immunol. 1979 Jan;35(1):45-52.

Fabre RA, Perez TM, Aguilar LD, Rangel MJ, Estrada-Garcia I, Hernandez-Pando R, Estrada Parra S. Transfer factors as immunotherapy and supplement of chemotherapy in experimental pulmonary tuberculosis. Clin Exp Immunol. 2004 May;136(2):215-23.

Georgescu C. Effect of long-term therapy with transfer factor in rheumatoid arthritis. Med Interne. 1985 Apr-Jun;23(2):135-40.

Holick MF.Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006 Sep;92(1):49-59.

Hughes RA. Immunological treatment of multiple sclerosis. J Neurol. 1983;230(2):73-80.

Hyun KJ, Kondo M, Koh T, Tokura H, Tamotsu S, Oishi T.Effect of dim and bright light exposure on some immunological parameters measured under thermal neutral conditions. Chronobiol Int. 2005;22(6):1145-55.

Iushkova TA, Iushkov VV. The immunomodulating activity of a transfer-factor preparation transflavin, specific to tick-borne encephalitis virus. Zh Mikrobiol Epidemiol Immunobiol. 1998 Mar-Apr;(2):83-5.

Jones JF, Jeter WS, Fulginiti VA et al. Treatment of childhood combined Epstein-Barr virus/cytomegalovirus infection with oral bovine transfer factor. Lancet 1981;2:122-124.

Katoch K. Immunotherapy of leprosy. Indian J Lepr. 1996 Oct-Dec;68(4):349-61.

Kidd PM. Autism, an extreme challenge to integrative medicine. Part 2: medical management. Altern Med Rev. 2002 Dec;7(6):472-99.

Kirkpatrick CH. Transfer factors: identification of conserved sequences in transfer factor molecules. Mol Med. 2000 Apr;6(4):332-41.

Kirkpatrick CH. Activities and characteristics of transfer factors. Biotherapy. 1996;9(1-3):13-6.

Kirkpatrick CH. Structural nature and functions of transfer factors. Ann N Y Acad Sci. 1993 Jun 23;685:362-8.

Kirkpatrick CH. Biological response modifiers. Interferons, interleukins, and transfer factor. Ann Allergy. 1989 Mar;62(3):170-6.

Lang I, Nekam H, Gergely P et al. Effect of in vivo and in vitro treatment with dialyzable leukocyte extracts on human natural killer cell activity. Clin Immunol and Immunopathol 1982;25:139-144.

Lawrence HS, Borkowsky W. Transfer factor--current status and future prospects. Biotherapy. 1996;9(1-3):1-5.

Louie E, Borkowsky W, Klesius PH, Haynes TB, Gordon S, Bonk S, Lawrence HS. Treatment of cryptosporidiosis with oral bovine transfer factor. Clin Immunol Immunopathol. 1987 Sep;44(3):329-34.

McMeeking A, Borkowsky W, Klesius PH, Bonk S, Holzman RS, Lawrence HS. A controlled trial of bovine dialyzable leukocyte extract for cryptosporidiosis in patients with AIDS. J Infect Dis. 1990 Jan;161(1):108-12.

Meduri R, Campos E, Scorolli L, De Vinci C, Pizza G, Viza D. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy. 1996;9(1-3):61-6.

Ojeda MO, Fernandez-Ortega C, Rosainz MJ. Dialyzable leukocyte extract suppresses the activity of essential transcription factors for HIV-1 gene expression in unstimulated MT-4 cells. Biochem Biophys Res Commun. 2000 Jul 14;273(3):1099-103.

Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Perez R, Arrieta O. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res. 2005 Dec;24(4):575-83.

Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D. Transfer factor prevents relapses in herpes keratitis patients: a pilot study. Biotherapy. 1994;8(1):63-8.

Pizza G, Amadori M, Ablashi D, De Vinci C, Viza D. Cell mediated immunity to meet the avian influenza A (H5N1) challenge. Med Hypotheses. 2006;67(3):601-8.

Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R. Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses. Biotherapy. 1996;9(1-3):67-72.

See D, Mason S, Roshan R. Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol Invest. 2002 May;31(2):137-53.

Siegel SD, Antoni MH, Fletcher MA, Maher K, Segota MC, Klimas N. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup? J Psychosom Res. 2006 Jun;60(6):559-66.

Sperner-Unterweger B. Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. Drugs. 2005;65(11):1493-520.

Spitler LE. Transfer factor: failure to transfer reactivity in normal human subjects. Clin Exp Immunol. 1980 Mar;39(3):708-16.

Steele RW, Myers MG and Monroe VM. Transfer factor for the prevention of varicella-zoster infection in childhood leukemia. N Engl J Med 1980;303:355-359.

Stiff, LA. Treating Chronically Ill Patients with Transfer Factor: An Exclusive Interview with Dr. Carol Ann Ryser, M.D. Originally published 10-31-2001. Accessed December 22, 2006 at www.prohealth.com/library/showarticle.cfm/ID/103

Viza D, Vich JM, Phillips J et al. Orally administered specific transfer factor for the treatment of herpesvirus infections. Lymphok Res 1985;4:27-30.

Wagner G, Knapp W, Gitsch E, Selander S. Transfer factor for adjuvant immunotherapy in cervical cancer. Cancer Detect Prev Suppl. 1987;1:373-6.

Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmacher T. Illness, cytokines, and depression. Ann N Y Acad Sci. 2000;917:478-87.

Xu YP, Zou WM, Zhan XJ, Yang SH, Xie DZ, Peng SL. Preparation and determination of immunological activities of anti-HBV egg yolk extraction. Cell Mol Immunol. 2006 Feb;3(1):67-71.